drugset / Trial / NCT07118709
A Study of KC1086 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1086 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into two parts: dose-escalation phase and dose-expansion phase.
Timeline
- Start
- 2025-08
- Primary completion
- 2028-08
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KC1086 | Unknown | 1 mg | Oral |
| Subject | KC1086 | Unknown | 2 mg | Oral |
| Subject | KC1086 | Unknown | 4 mg | Oral |
| Subject | KC1086 | Unknown | 6 mg | Oral |
| Subject | KC1086 | Unknown | 8 mg | Oral |
Indications
No indication recorded.